https://epz015938inhibitor.com..../examination-of-a-ch
DU145-TxR and DU145-TxR/CxR cells, subjected to cabazitaxel treatment and concurrently exposed to a CCR2 antagonist, exhibited diminished STAT3 phosphorylation, as evident from Western blot analyses. By silencing CCL2 with siRNA in DU145-TxR and DU145-TxR/CxR cells, the migratory capacity was reduced, primarily because of the inactivation of STAT3 and p38. CCL2 induced AKT activation, and CCR2 antagon